Results 101 to 110 of about 4,889,938 (291)
British Journal of Clinical Pharmacology, EarlyView.Aims In this study, we examined the effects of assigning partial credit to selected answer choices on student performance and perceptions in a pharmacology course using Type A multiple‐choice questions (MCQs). Methods Partial credit scoring was incorporated into quizzes and exams in a 10‐week pharmacology course for postbaccalaureate premedical ...
Stephen D. Schneid +2 more
wiley +1 more source
Response to: Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan) [PDF]
, 2020 Luigi Petramala, Claudio Letizia
openalex +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić +4 more
wiley +1 more source
IL-6 Deficiency Protects Against Angiotensin II–Induced Endothelial Dysfunction and Hypertrophy [PDF]
, 2007 Laura I. Schrader +4 more
openalex +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims This study investigated factors associated with and outcomes of combined loop diuretics with hydrochlorothiazide (HCTZ) for acute decompensated heart failure (ADHF). Methods In this retrospective study, adults hospitalized for ADHF and who received intravenous loop diuretics between January 2016 and March 2023 were enrolled.
Chia‐Chen Hsu +6 more
wiley +1 more source
The Docking of Arg2 of Angiotensin II with Asp281 of AT1 Receptor Is Essential for Full Agonism [PDF]
, 1995 Ying-Hong Feng +5 more
openalex +1 more source
Trends in first‐line monotherapy and combination therapy for hypertension in UK primary care
British Journal of Clinical Pharmacology, EarlyView.Aims Debate remains about the optimal initial treatment strategy for hypertension. Most guidelines recommend first‐line combination therapy for most patients. However, the UK's National Institute for Health and Care Excellence recommends first‐line monotherapy for all patients.
Kyle Johnson +4 more
wiley +1 more source
Angiotensin II—Real-Life Use and Literature Review
MedicinaAngiotensin II is a recently introduced vasopressor, which has been available since 2017. The novelty and the relatively high cost of angiotensin II currently limit its broader application.
Andreja Möller Petrun, Andrej Markota
doaj +1 more source
Systemic candesartan reduces brain angiotensin II via downregulation of brain renin–angiotensin system [PDF]
, 2009 Nicolas Pelisch +9 more
openalex +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Glucagon‐like peptide‐1 (GLP‐1) and glucagon dual receptor agonists are in clinical development for a range of metabolic conditions, including type 2 diabetes and obesity. The cardiovascular actions at these receptors are well studied, but less is known about their combination.
James Goodman +13 more
wiley +1 more source